Revitas, Inc., the leading provider of integrated solutions for contract, revenue, and compliance management, today announced that Amneal Pharmaceuticals, one of the largest generic drug suppliers in the U.S., has selected the Revitas suite of revenue management solutions to support global growth and meet expanded business requirements.
Release date- 17122014- Toronto, ON- Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for filing the company's application for pegfilgrastim, a biosimilar version of Amgen's Neulasta. The product has been jointly developed with Intas Pharmaceuticals Ltd. The applic
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution, 2%/ 0.5%, the therapeutic equivalent to the reference listed drug, Cosopt Ophthalmic Solution, 2%/ 0.5%, of Oak Pharmaceutica
The guidance describes how FDA plans to implement the requirements for the electronic submission of standardized study data contained in certain submissions under new drug applications, abbreviated new drug applications, biologics license applications, and investigational new drug applications. ADDRESSES: Submit written requests for single copies..
Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, announces today that it is launching Putney Carprofen Chewable Tablets, its FDA approved generic of Zoetis' popular Rimadyl Chewable Tablets. With this product approval, the Company's fourth in less than three
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today updated that the pictures of TPI's Qionglai Facility are available on the front page of www.tianyinpharma.com. TPI currently manufactures..
Believed to be the First Company to Have a Biosimilar Filing Accepted for Review of Amgen's Neulasta . TORONTO, Dec. 17, 2014/ CNW/- Apotex Inc., the largest Canadian owned pharmaceutical company, announced today that the US Food and Drug Administration has accepted for filing the company's application for pegfilgrastim, a biosimilar version of A
Report Details Biosimilar drugs discover trends and segments with highest potential revenues Do you want to find sales potentials of biosimilars? Visiongain's updated report gives you revenue predictions for those biological drugs from 2014, helping you stay ahead. For those therapies you find financial data, R&D trends, opportunities and sell
Consequently, Teva will be compelled to wait until June 2015 before being allowed to launch the generic version of the arthritis, inflammation and chronic pain treatment, which earns Pfizer $3 billion annually. Last week Teva had announced that it would be immediately launching an exclusive version of generic Celebrex after becoming the first to re
Teva is the world's largest generic drug manufacturer and a top-20 global pharmaceutical company. The risk remains that Teva's top-selling drug, Copaxone, could face generic competition in the U.S. at any time and by May 2015 in most of Europe. However, this risk has been mitigated by Teva's successful conversion of nearly two-thirds of U.S. pa
The Report Generic and Innovative Drugs Market in CIS Countries 2014 Russia, Ukraine and Kazakhstan Development Forecasts for 2014-2019 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.- MarketResearchReports.bizAlbany, NY 12/17/2014 Compare and analyse generic and innovati
Mylan Inc., one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 33 rd Annual Healthcare Conference on Tuesday Jan. 13, 2015, in San Francisco. The presentation is scheduled to begin at 7:30 p.m. ET on Tuesday Jan. 13, 2015.
New Monoclonal Antibodies Findings Reported from Covance Laboratories Inc.. PF-05280014 is being developed as a potential biosimilar to trastuzumab products marketed in the United States and European Union. " Our news editors obtained a quote from the research from Covance Laboratories Inc., "Nonclinical studies were designed to evaluate the simila
New Pharmacoeconomics Study Results Reported from Erasmus University. Our news journalists obtained a quote from the research from Erasmus University, "At this moment, the uptake of biosimilars in Belgium is limited, with market shares close to 0%. This study aimed to identify the barriers that impede the uptake of biosimilars in Belgium.
With major cancer drugs slated for patent expirations in the next few years and big pharmas such as Eli Lilly foraying into the generics industry, generics are going to be the next big thing in the field of oncology. Recently, ScinoPharm Taiwan and Coland have formed a strategic partnership in order to develop a series of generic oncological drugs
AstraZeneca's Avlon plant is used to make the active pharmaceutical ingredients for two of the firm's brands. Meanwhile generic versions of the other drug produced in Avonmouth are already available in the UK and US. The drug, Seroquel, is licensed in the UK for the treatment of bipolar disorder and schizophrenia.
The December issue of Atlantic Information Services, Inc.' s Specialty Pharmacy News offers coverage of a recent conference on biosimilars, drugs that are highly similar to and less expensive than brand-name biologic drugs and use an abbreviated pathway for the Food and Drug Administration's approval. At Rx Innovation: A Discussion on Biosimilars,
Wilshire Pharmaceuticals confirmed that it has been sued by Allergan and Vistakon Pharmaceuticals in connection with Wilshire's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration for Alcaftadine 0.25 percent. Wilshire Pharmaceuticals is a generic pharmaceutical company. It is a subsidiary of Arbor...
Reddy s Laboratories announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE tablets in the US market on December 15, 2014, approved by the United States Food& Drug Administration. The VALCYTE tablets brand had U.S. sales of approximately $440 Million MAT for the most rece
PCI Synthesis, Inc., a manufacturer of new chemical entities, generic active pharmaceutical ingredients, and other specialty chemical products, announced that it is a sponsor and steering committee member of the New England CRO/CMO Council, along with Averica Discovery Services, Organix TGA Sciences, Inc. and CE3. The non-profit New England CRO/CMO
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today updates that it expects to receive the formal Good Manufacturing Practice certificate for its Qionglai Facility's from the China Food& Drug
Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today updates that it expects to receive the formal Good Manufacturing Practice certificate for its Qionglai Facility's from the China Food& Drug..
VANC Pharmaceuticals Inc. is pleased to announce that it has received Notice of Compliance from Health Canada for 7 additional generic molecules, bringing the Company's generic portfolio to a total 30 molecules. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company focused on the global biosimilar market, today reported financial results and reviewed corporate events for the quarter ended September 30, 2014. Received two milestone payments under existing collaboration with Baxter Healthcare Corporation: In July 2014, achieved a $15.
WASHINGTON, DC- The U.S. Senate Special Committee on Aging unveiled a new bipartisan report today that focuses on ways to increase the use of generic drugs within the Medicare Part D program. In addition to the report, the committee is calling on the Government Accountability Office to examine what's behind recent price increases for certain generi